.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The NAVIGATOR trial evaluated tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin, in adults and adolescents with severe uncontrolled asthma. Over the study period, tezepelumab produced a substantial reduction in annualized asthma exacerbations compared with placebo and improved measures including lung function. Importantly, benefit was observed across a range of baseline biomarker profiles, including patients with lower eosinophil counts, supporting the idea that upstream treatment of airway inflammation can extend beyond a single biomarker-defined phenotype. For HCPs, the practical implication is that severe asthma assessment should not rely on one laboratory value in isolation. Exacerbation history, oral corticosteroid exposure, inhaler adherence and technique, comorbidities, and type 2 biomarkers all contribute to the decision about advanced therapy. The study is particularly aligned with the conference focus on phenotyping in everyday practice and on the emerging biologics era. It also supports a stepwise approach: confirm the diagnosis, optimize inhaled therapy and technique, address modifiable factors, and then consider biologic therapy for patients who remain uncontrolled and meet appropriate clinical criteria.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The NAVIGATOR trial evaluated tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin, in adults and adolescents with severe uncontrolled asthma. Over the study period, tezepelumab produced a substantial reduction in annualized asthma exacerbations compared with placebo and improved measures including lung function. Importantly, benefit was observed across a range of baseline biomarker profiles, including patients with lower eosinophil counts, supporting the idea that upstream treatment of airway inflammation can extend beyond a single biomarker-defined phenotype. For HCPs, the practical implication is that severe asthma assessment should not rely on one laboratory value in isolation. Exacerbation history, oral corticosteroid exposure, inhaler adherence and technique, comorbidities, and type 2 biomarkers all contribute to the decision about advanced therapy. The study is particularly aligned with the conference focus on phenotyping in everyday practice and on the emerging biologics era. It also supports a stepwise approach: confirm the diagnosis, optimize inhaled therapy and technique, address modifiable factors, and then consider biologic therapy for patients who remain uncontrolled and meet appropriate clinical criteria.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
3 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
